Webster kindergarteners join together to support classmate battling cancer
ROCHESTER, N.Y. (WROC) — A kindergarten class at DeWitt Road School is banding together in support of one their classmates — with a lemonade stand.
Tacianna Indovina said back in March, what started as an ordinary school day turned heartbreaking for 6-year-old Briella.
When Briella broke her leg, she and her family were at the hospital when the doctor gave them shocking news.
'[They] were shocked to learn that she likely had osteosarcoma bone cancer, two hours into their emergency room visit,' Indovina told News 8.
Since that day, Briella has had multiple rounds of chemotherapy, 'facing each one with bravery and strength.'
Briella's story resonated with the DeWitt Road Elementary School, and so they could show their support — Briella's kindergarten class is organizing a lemonade stand fundraiser on June 1 to benefit Briella and her family.
'You can show your support by donating directly to Briella's family — @Critt5833 on Venmo,' Indovina said.
'This is about coming together for a little girl who's going through so much,' said one of the parents organizing the event. 'We want Briella and her family to feel the strength and support of the whole community.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.
Medscape
2 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
Washington Post
2 hours ago
- Washington Post
New York lawmakers approve bill that would allow medically assisted suicide for the terminally ill
ALBANY, N.Y. — Terminally ill New Yorkers would have the legal ability to end their own lives with pharmaceutical drugs under a bill passed Monday in the state Legislature. The proposal, which now moves to the governor's office, would allow a person with an incurable illness to be prescribed life-ending drugs if he or she requests the medication and gets approval from two physicians. A spokesperson for New York Gov. Kathy Hochul said she would review the legislation.
